淋巴瘤免疫治疗的现状及展望  

Current situation and prospect of immunotherapy for lymphoma

作　　者：吴德沛[1,2] 陈晓晨[1,2] WU Depei;CHEN Xiaochen(Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology,Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu, China;State Key Laboratory of Radiation Medicine and Protection,Soochow University, Suzhou, 215123, Jiangsu, China)

机构地区：[1]苏州大学附属第一医院血液科江苏省血液研究所国家卫生部血栓与止血重点实验室,江苏苏州215006 [2]苏州大学省部共建放射医学与辐射防护国家重点实验室,江苏苏州215123

出　　处：《山东大学学报（医学版）》2019年第7期13-20,共8页Journal of Shandong University:Health Sciences

基　　金：国家重点研发计划(2017YFA0104502,2017ZX09304021);江苏省医学杰出人才项目(JCRCA2016002);江苏省创新能力建设专项(BM2015004);江苏省科教强卫工程-临床医学中心(YXZXA2016002)

摘　　要：淋巴瘤是最常见的血液系统恶性肿瘤之一,其亚型众多,具有高度异质性。既往淋巴瘤的治疗多采取化疗、放疗及手术在内的常规方法,但难治/复发一直是临床面临的棘手问题。近年来,免疫治疗的突破性进展给淋巴瘤患者带来新的希望。综述了近年来靶向淋巴细胞分化抗原的单克隆抗体及耦联药物,免疫检查点阻断剂及嵌合抗原受体T细胞等多种免疫治疗方法在淋巴瘤中的应用现状及未来展望。Lymphoma is one of the most common hematological malignancies which has many subtypes and high heterogeneity. Traditional treatments include chemotherapy, radiotherapy and surgery. Patients with relapsed, refractory or advanced stage lymphoma still have dismal prognosis. In recent years, the development of immunotherapies for lymphoma has brought patients new hope. This paper reviews the current and novel immunotherapies for lymphoma, including monoclonal antibody therapy, immune checkpoint blockers, and chimeric antigen receptor T cells therapies.

关 键 词：淋巴瘤 免疫治疗 单克隆抗体治疗 免疫检查点 嵌合抗原受体T细胞治疗 

分 类 号：R733.4[医药卫生—肿瘤]